Interestingly, cellular chemosensitivity towards doxorubicin and paclitaxel was increased when survivin was targeted by miR-485-5p, while cisplatin resistance was claimed to be attributed to PI3K/Akt signaling targeted by miR-485-5p in ovarian cancer [64, 67]. The gene discussed is BIRC5; the disease is ovarian carcinoma.